Lead sponsor
The Affiliated Hospital of Xuzhou Medical University
3 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
3
Trials led
1
Active
938
Total enrollment
1
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Not applicable
3
Trials by status
Recruiting
1
Completed
2
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
Effect of Gene Polymorphisms on GLP-1 Receptor Agonists Response in Patients With T2DMBMI 20-35not applicableCompleted338
Renoprotective Effects of Dulaglutide in Patients With Type 2 Diabetic NephropathyUACR ≥30not applicableCompleted300
Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DMBMI 20-35not applicableRecruiting300